NEW YORK (TheStreet) -- Sarepta Therapeutics (SRPT - Get Report) shares are up 3.5% to $21.84 on Wednesday following the news that the first case of the deadly Ebola virus has reached the U.S.

The CDC confirmed that a patient in Texas has been diagnosed with Ebola, months after the disease has ravaged Africa and claimed over 3,000 lives.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Sarepta Therapeutics has been working on an Ebola vaccine and said that it has enough doses of the treatment to treat 100 patients.

U.S. officials have said that they would consider using experimental drugs to treat the patient in Texas.

TheStreet Ratings team rates SAREPTA THERAPEUTICS INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:

"We rate SAREPTA THERAPEUTICS INC (SRPT) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

SRPT Chart SRPT data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.